The purpose of this clinical trial is to evaluate SPR720 in a double-blind, placebo-controlled study in healthy subjects consisting of single ascending dose and multiple ascending dose cohorts. SPR720 is an orally administered antimicrobial agent being developed for the treatment of nontuberculous mycobacterial (NTM) infections. The advancement of SPR720 into the Phase 1 clinical assessment was...Read More
Arikayce for Nontuberculous Mycobacteria The purpose of this randomized, placebo-controlled study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of liposomal amikacin for inhalation (LAI) versus placebo in patients with recalcitrant Mycobacterium avium complex lung disease. The primary outcome measure is proportion of subjects with culture...Read More
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Clofazimine has been used for many years off-label against other Mycobacteria, including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent...Read More
WHAT IS NTM?
“NTM” is short for Nontuberculous Mycobacteria. NTM disease is a serious chronic lung illness.